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Objective: To investigate immunohistochemically the expression of neural cell adhesion molecule (NCAM), which
has been identified as a signaling receptor with frequent reactivity in ameloblastomas (AB), in a series of keratin-producing
odontogenic cysts (KPOCs).
Material and methods: Immunohistochemical expression of NCAM, using a monoclonal antibody, was determined in a
series of 58 KPOCs comprising 12 orthokeratinized odontogenic cysts (OOCs) and 46 keratocystic odontogenic tumors
(KCOTs), corresponding to 40 non-syndromic KCOT (NS-KCOTs) and 6 syndromic KCOT (S-KCOTs), associated with nevic
basocellular syndrome (NBCS).
Results: NCAM expression was negative in all OOCs, but 36.45% of KCOTs exhibited focal and heterogeneous expression
at the basal cell level, as well as in basal budding areas and the basal cells of daughter cysts. The latter two locations were
especially applicable to S-KCOTs, with focal NCAM reactivity occurring in 66.66% of cases.
Conclusions: Aberrant NCAM expression, in KCOTs but especially in S-KCOTs, together with its immunomorphological
location, suggests that this adhesion molecule and signaling receptor plays a role in the pathogenesis of KCOTs, with a
probable impact on lesional recurrence.
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ImmunohistochemistryIntroduction
Keratin-producing odontogenic cysts (KPOCs) form a
heterogeneous group of cystic lesions that are often ag-
gressive in character, with high rates of recurrence and
multifocality [1]. The lesional spectrum of KPOCs in-
cludes odontogenic keratocysts, that according to last
World Health Organization (WHO) guidelines [2] are also
referred to as keratocystic odontogenic tumors (KCOTs),
in accordance with the fact that KCOTs are true tumoral
growths. Effective management of these cystic lesions is
subject to frequent discussion [3] and malignant trans-
formation is possible, albeit very rare [4].
NCAM (neural cell adhesion molecule), also known as
CD56, was originally characterized as a cell-surface glyco-
protein member of the immunoglobulin superfamily, im-
plicated in calcium-independent intercellular adhesion [5]* Correspondence: fco.jose.vera@uv.es
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unless otherwise stated.and expressed in a wide variety of cells [6]. However, in
the past decade the traditional view of NCAM has been
challenged, such that it is now also considered a signaling
receptor that impacts upon cellular migration, prolifera-
tion, differentiation, and survival, thereby playing a role in
different models of tumor growth [7].
NCAM immunoreactivity in ameloblastomas within
odontogenic tumors has been reported with very high
frequency [8-11], and has also been observed in certain
ameloblastic carcinomas [9]. In contrast, NCAM reactiv-
ity is indicated as relatively infrequent in KCOTs [10,11].
The aim of the present study was to assess the immu-
nohistochemical expression of NCAM in a series of
keratin-producing odontogenic cysts (KPOCs), and to
evaluate the possible significance of adhesion molecule
reactivity in this heterogeneous group of odontogenic
cysts.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 NCAM expression in KPOC
Lesional Type No. cases NCAM+ cases (%) Recurrence
OOC 12 0/12 (0,00%) 0,00%
S- and NS-KCOT 46 16/46 (36,95%) 43,47%
NS-KCOT 40 12/40 (30,00%) 35,00%
S-KCOT 6 4/6 (66,66%) 100,00%
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We studied 58 cases of KPOC diagnosed over a period
of 10 years at the Department of Pathology of La Fe
University Hospital, Valencia, Spain. Histological ma-
terial was retrieved from storage. Our work formed
part of a project previously approved by our Ethics
Committee for Biomedical Research (protocol no.
2013/0045).
We selected KPOC cases using a pathological diagno-
sis database (Pat Win®, ver. 4.1.4), and performed a 10-
year retrospective search employing the following search
terms: “keratinized cyst”, “keratocyst”, “primordial cyst”,
“keratocystic odontogenic tumor (KCOT)”, and “ortho-
keratinized odontogenic cyst (OOC)”. All of these terms
have been used over time to describe various lesions, in-
cluding KPOCs [4,12].
All original histological sections were reviewed micro-
scopically by two observers, and were reclassified according
to the WHO (2005) criteria [2], into 46 examples of KCOT
and 12 of OOC. In all KCOT cases the presence or absence
of daughter/satellite cysts in the cystic wall, and/or budding
areas of the basal layer, was noted because the morpho-
logical features of these lesions have been implicated in
their recurrence [13,14].
Clinical and radiological data of all patients were col-
lected using the Mizar® (ver. 2.0) medical records platform,
in conjunction with the viewfinder software package Luna®
(ver. 3.0). Clinical/radiological follow-up findings, the
number of recurrences, and any clinical, pathological, or
genetic data suggesting syndromic association were re-
trieved. Following verification of the diagnostic criteria of
Kimonis et al. [15] for nevic basocellular syndrome
(NBCS), 6 of the 46 KCOT were considered syndromic
KCOTs (S-KCOTs). The remaining 40 cases qualified as
sporadic or non-syndromic KCOTs (NS-KCOTs). There-
fore, the biopsy material finally included was as follows: 12
OOC; 40 NS-KCOT; and 6 S-KCOT.
Sections of 5-μm thickness were cut from the original
paraffin-embedded blocks and mounted on poly-L-
lysine-coated glass slides prior to immunohistochemical
staining, performed using the lyophilized mouse monoclo-
nal antibody NCL-CD56-504 (clone CD564; Novocastra™,
Leica Biosystems, Newcastle upon Tyne, UK), at 1/50 dilu-
tion, and with a 60-min incubation time. Epitope retrieval
proceeded at 97°C for 20 min, in a citrate buffer of pH 9.
Immunostaining was visualized using the high-pH EnVision
FLEX system (Dako®, Glostrup, Denmark): hematoxylin
was used for counterstaining. Tonsil sections served as
positive staining controls: the negative controls were
mock-stained test sections (the primary antibody was
replaced by PBS).
NCAM (CD56) immunostaining was semi-quantitatively
assessed on a scale ranging between 0 and 3+ (0 = absent;
1+ =weak; 2+ =moderate; 3+ = intense), and also classifiedas diffuse (>50% of cells), extensive (10-50% of cells) or
focal (<10% of cells expressing NCAM).
NCAM immunohistochemical results for the different
KPOC subtypes expressed as categorical variables with
numbers and percentages, as well as associations be-
tween NCAM expression and recurrence, were com-
pared using Firth’s logistic regression test. Statistical
analyses were performed using the SPSS for Windows
software package (ver. 14.0; SPSS Inc., Chicago, IL). A
value of p <0.05 was taken to indicate statistical significance.
Results
Of 58 KPCOs, only 16 cases (27,58%) dysplayed NCAM
expresión at the of epithelial level and inmunoreactivity
was in positive cases of focal character (<10% of cells
expressing NCAM) with a weak (1+) to moderate (2+)
intensity, and always demostrating a heterogeneous dis-
tribution within the structure of the cystic lesion.
NCAM expression was absent in all 12 OOC cases,
with the epithelial lining of the cysts entirely negative
for CD56. In contrast, focal NCAM reactivity was ob-
served at the epithelial level in 16 of 46 KCOT cases
(36.95%). There was a significant difference in NCAM
expression in cases of OOC vs. KCOT (p = 0.012).
NCAM immunostaining was differentially expressed
in NS- and S-KCOTs: four of the six cases of S-KCOT
(66.66%) exhibited focal NCAM reactivity at the epithe-
lial level, in contrast to only 12 of the 40 (30%) cases of
NS-KCOT (Table 1). OOC did not recur in any case
during clinical/radiological follow-up at 39.2 ± 26.01 m.
In contrast, all cases of S-KCOT recurred at a mean
follow-up of 112 ± 76.1 m. In NS-KCOT0 cases, the re-
currence rate was 35% at a mean follow-up of 29.6 ±
31.04 m. When analyses were performed independent of
lesional subtype, there was no association between re-
currence and NCAM expression (p = 0.52).
In positive cases, NCAM expression was always epi-
thelial, with weak (1+) to moderate (2+) intensity and a
heterogeneous and focal distribution (Figures 1A and
1B). NCAM positivity (Table 2) was most frequent in
the basal layer of cystic epithelium, followed by areas of
basal budding (Figures 2A and 3A-D) and the basal portion
of daughter cysts or satellite epithelial nests (Figures 2B and
4A-D). In NCAM-positive S-KCOT cases (four of six),
NCAM positivity was discontinuous, weak or moderate, in
the locations indicated above, although only 50% of satellite
Figure 1 KCOT showing NCAM reactivity at basal cells with a discontinous pattern (A) and occasional extension to suprabasal level (B).
NCAM 200×.
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Similarly, in NS-KCOTs, the most frequent NCAM-
positive location was the basal cell layer of the cystic
lining (observed in all cases exhibiting NCAM positiv-
ity), followed by areas of basal budding (n = 4) and
basal portions of daughter cysts (n = 3).Table 2 NCAM + location in KPOC
Lesional Type No. cases NCAM+ cases (%) Basa
OOC 12 0/12 (0,00%) 0/12
S- and NS-KCOT 46 16/46 (36,95%) 16/46
NS-KCOT 40 12/40 (30,00%) 12/40
S-KCOT 6 4/6 (66,66%) 4/6Discussion
Neural cell adhesion molecule (NCAM), a member of
the immunoglobulin superfamily adhesion molecule, is
expressed by a wide variety of neuroectodermal and
mesenchymal cells [6]. Originally, NCAM was exclu-
sively characterized as a mediator of cell-cell adhesion,l cells Basal budding Daughter cysts
(0,00%) 0/12 (0,00%) 0/12 (0,00%)
(34,78%) 7/46 (15,21%) 6/46 (13,04%)
(30,00%) 4/40 (10,00%) 3/40 (7,50%)
(66,66%) 3/6 (50,00%) 3/6 (50,00%)
Figure 2 Epithelial budding (A) and daughter microcyst (B) in KCOT. HE 200 and 250×.
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that impacts upon cellular adhesion, migration, prolifer-
ation, apoptosis, differentiation, and survival. NCAM is
involved in various models of tumorigenesis [7], including
certain types of odontogenic tumor: NCAM expression
has been reported in certain ameloblastic carcinomas [9],
and especially in the outer columnar cells of ameloblas-
toma (AB) [8-11]. This expression could be indicative of
neuroectodermal differentiation in AB [10], especially con-
sidering the fact that neural crest cells are associated with
tooth development, particularly ectomesenchymal differ-
entiation in tooth germs [15].
The purpose of the present study was to assess the
presence and significance of NCAM reactivity in a seriesof KPOCs. Our results highlight a total absence of NCAM
expression in OOCs, a form of KPOCs characterized by
orthokeratotic keratinization, reduced proliferative activity
and non-recurrence [16,17]. Recurrence was not observed
for any case of OOC, but in KCOTs, a form of KPOC now
considered as a true odontogenic tumor [1,2,4], we ob-
served focal and heterogeneous NCAM expression in
36.95% of cases, a significantly higher rate than OOC. Prior
to our investigation, only two studies assessed NCAM ex-
pression in odontogenic cysts. Cairns et al. [11] reported
NCAM expression in only 5.26% of KCOTs, with focal
NCAM reactivity occurring at the basal cell level; in con-
trast, AB exhibited high levels of NCAM reactivity. More
recently, Kusafuka et al. reported that 50% of KCOTs
Figure 3 KCOT showing epithelial buds (A) arising of basal cells (B and C) displaying NCAM reactivity with a predominantly membranous
pattern (D). (NCAM, 200 and 400×).
Figure 4 NCAM reactivity in satellite epithelial nests of small size (A and B) as well as in basal cells of daughter cysts (C and D) located
in KCOT wall (NCAM, 200, 250 and 400x).
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sion at the basal cell level [10]. Our series therefore repre-
sented an intermediate rate of positive observations.
In our KCOT cases, NCAM expression was exclusively
focal and heterogeneous, with weak-to-moderate reactiv-
ity. Despite this limited, focal reactivity, our results dem-
onstrate NCAM expression in locations not described
previously: earlier studies noted NCAM reactivity only
in the basal cell layer of KCOTs [10,11]. Furthermore, in
one of these studies, which analyzed three cases of S-KCOT,
there was no relationship between NCAM expression and
this syndromic form of KCOT [11]. In contrast, we not only
observed discontinuous positivity in the basal portion of cys-
tic epithelium but also in areas of basal budding and in the
basal portion of daughter cysts, both of which are occasion-
ally detectable in KCOTs, and particularly in S-KCOTs.
Epithelial budding, arising from the basal layer of cys-
tic lining, is a peculiar morphological aspect of KCOT
that has been suggested as the source of daughter cysts;
[18-20] influences lesional recurrence; [13,14,21] and is
most frequently observed in S-KCOTs [22]. Aberrant
NCAM expression in epithelial buds and the basal por-
tion of daughter cysts of KCOTs was observed in 50% of
S-KCOTs and represents a possible influence on NCAM
expression in instances of lesion recurrence.
In our series, all S-KCOT cases recurred; in NS-KCOTs
the recurrence rate was 35%. NCAM expression was de-
tected in 66.66% and 32.50% of S- and NS-KCOTs, respect-
ively. Systematic review of cases of NS-KCOT indicated an
average recurrence rate of 28% [23], although rates were
heavily influenced by the duration of follow-up, and
especially by the type of treatment administered [3],
indicating that adequate management of NS-KCOTs
may prevent recurrence [2,24].
When we analyzed the relationship between NCAM
expression and recurrence independent of KPOC subtype,
there was no significant association. However, there was
an important limitation: observations were not treated
homogeneously due to the retrospective nature of the
series. Nevertheless, the fact that NCAM expression was
observed in morphological locations involved in recur-
rence [13,14,21] suggests a possible relationship between
NCAM expression and lesional recurrence. Further stud-
ies pertaining to NCAM expression, in larger series of
KCOTs treated with homogenous procedures or subjected
to prospective randomized analysis [25], are required to
obtain definitive conclusions. Likewise should be verify a
possible association between increased expression of CD56
and others markers [26,27] and genes [28] overexpressed in
KCOT.
A final interesting observation concerned NCAM ex-
pression in AB, another frequently recurring odonto-
genic tumor in which NCAM reactivity, in contrast to
KCOTs, is virtually certain [11]. AB and KCOTs havebeen considered two morphologically distinct odonto-
genic tumors [29]. However, certain morphological and
evolutionary data indicate a degree of overlap between
these tumors; [30] this similarity is clearly reflected in
so-called keratoameloblastoma [31,32], as well as in the
solid variant of KCOT [33], characterized by hybrid AB
and KCOT morphological features. Accordingly, aber-
rant NCAM expression in KCOTs could be indicative of
foci of ameloblastic differentiation. As suggested previ-
ously [27,34], collaborative studies (given the scarcity of
observations) concerning NCAM in keratoameloblasto-
mas are required to confirm if this is the case.
Conclusions
The present study investigated the immunomorphological
pattern of NCAM expression in KPOCs, and highlighted
that NCAM expression in OOCs is entirely absent. In
relation to KCOT our immunohistochemical analysis
indicated NCAM reactivity in locations not reported
previously (e.g., areas of basal budding and basal cells
of daughter cysts), especially with respect to S-KCOTs.
This suggests a possible role for this signaling molecule in
lesional recurrence in KCOTs. Futures studies using
homogeneously treated series of KCOT cases are required
to confirm the influence of NCAM on lesion recurrence,
as well as its potential utility as a marker of ameloblastic
differentiation.
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